Targets › SARS-COV-2
3 programs from 3 companies in 11 trials: 5 Phase 3, 3 Phase 4, 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: the race on SARS-COV-2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioNTech SE | Tozinameran Spike glycoprotein vaccine antigen | SARS-COV-2 | Phase 4 | COVID-19 Vaccines; COVID-19; Diabetes Mellitus, Type 1 | Apr 2027 |
| Novavax | NVX-CoV2705 Omicron JN.1 subvariant SARS-CoV-2 recombinant spike protein vaccine adjuvanted with Matri | SARS-COV-2 | Phase 4 | COVID-19 | – |
| Interna Therapeutics | Apo-Si-K170A-C76 small interfering RNA (siRNA) against SARS-CoV-2 | SARS-COV-2 | Phase 1 | SARS-CoV-2 (COVID-19) Infection | – |
COVID-19 (5) COVID-19 Vaccines (4) Diabetes Mellitus, Type 1 (1) SARS-CoV-2 (COVID-19) Infection (1)
other (1), small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.